Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Sethu Sankaranarayanan

Showing results (11-20 of 40) with videos related to

Pageof 4
Sort By:
Journal of Neuroscience Research|September 19, 2012
Characterization of plasma β-secretase (BACE1) activity and soluble amyloid precursor proteins as potential biomarkers for Alzheimer's diseaseGuoxin Wu, Sethu Sankaranarayanan, Jacky Wong, et al.
Acta Neuropathologica Communications|March 4, 2016
C1q-targeted inhibition of the classical complement pathway prevents injury in a novel mouse model of acute motor axonal neuropathyRhona McGonigal, Madeleine E Cunningham, Denggao Yao, et al.
Clinical Biochemistry|May 21, 2008
Decrease in age-adjusted cerebrospinal fluid beta-secretase activity in Alzheimer's subjectsGuoxin Wu, Sethu Sankaranarayanan, Kate Tugusheva, et al.
Investigative Ophthalmology & Visual Science|February 2, 2023
Pharmacokinetic and Target Engagement Measures of ANX007, an Anti-C1q Antibody Fragment, Following Intravitreal Administration in Nonhuman PrimatesAnita Grover, Sethu Sankaranarayanan, Vidhu Mathur, et al.
Archives of Neurology|August 13, 2008
Elevated cerebrospinal fluid BACE1 activity in incipient Alzheimer diseaseHenrik Zetterberg, Ulf Andreasson, Oskar Hansson, et al.
Clinical Pharmacology in Drug Development|May 16, 2023
A Phase 1 First-in-Human Single-Ascending-Dose Trial With ESB1609, a Selective Agonist to the Sphingosine-1-Phosphate Receptor 5Nicholas P France, Christopher Rubino, M Courtney Safir, et al.
Plos One|October 12, 2013
Characterization of novel CSF Tau and ptau biomarkers for Alzheimer's diseaseJere E Meredith, Sethu Sankaranarayanan, Valerie Guss, et al.
The Journal of Neuroscience : the Official Journal of the Society for Neuroscience|May 1, 2015
Centrally Delivered BACE1 Inhibitor Activates Microglia, and Reverses Amyloid Pathology and Cognitive Deficit in Aged Tg2576 MiceDeepak R Thakker, Sethu Sankaranarayanan, Marcy R Weatherspoon, et al.
NPJ Parkinson'S Disease|October 25, 2024
CSF d18:1 sphingolipid species in Parkinson disease and dementia with Lewy bodies with and without GBA1 variantsStefanie Lerche, Isabel Wurster, Enza Maria Valente, et al.
Journal of Alzheimer'S Disease : JAD|March 23, 2011
Tau transgenic mice as models for cerebrospinal fluid tau biomarkersDonna M Barten, Gregory W Cadelina, Nina Hoque, et al.
Pageof 4

Showing results (11-20 of 40) with videos related to

Sort By:
Pageof 4
Journal of Neuroscience Research|September 19, 2012
Characterization of plasma β-secretase (BACE1) activity and soluble amyloid precursor proteins as potential biomarkers for Alzheimer's diseaseGuoxin Wu, Sethu Sankaranarayanan, Jacky Wong, et al.
Acta Neuropathologica Communications|March 4, 2016
C1q-targeted inhibition of the classical complement pathway prevents injury in a novel mouse model of acute motor axonal neuropathyRhona McGonigal, Madeleine E Cunningham, Denggao Yao, et al.
Clinical Biochemistry|May 21, 2008
Decrease in age-adjusted cerebrospinal fluid beta-secretase activity in Alzheimer's subjectsGuoxin Wu, Sethu Sankaranarayanan, Kate Tugusheva, et al.
Investigative Ophthalmology & Visual Science|February 2, 2023
Pharmacokinetic and Target Engagement Measures of ANX007, an Anti-C1q Antibody Fragment, Following Intravitreal Administration in Nonhuman PrimatesAnita Grover, Sethu Sankaranarayanan, Vidhu Mathur, et al.
Archives of Neurology|August 13, 2008
Elevated cerebrospinal fluid BACE1 activity in incipient Alzheimer diseaseHenrik Zetterberg, Ulf Andreasson, Oskar Hansson, et al.
Clinical Pharmacology in Drug Development|May 16, 2023
A Phase 1 First-in-Human Single-Ascending-Dose Trial With ESB1609, a Selective Agonist to the Sphingosine-1-Phosphate Receptor 5Nicholas P France, Christopher Rubino, M Courtney Safir, et al.
Plos One|October 12, 2013
Characterization of novel CSF Tau and ptau biomarkers for Alzheimer's diseaseJere E Meredith, Sethu Sankaranarayanan, Valerie Guss, et al.
The Journal of Neuroscience : the Official Journal of the Society for Neuroscience|May 1, 2015
Centrally Delivered BACE1 Inhibitor Activates Microglia, and Reverses Amyloid Pathology and Cognitive Deficit in Aged Tg2576 MiceDeepak R Thakker, Sethu Sankaranarayanan, Marcy R Weatherspoon, et al.
NPJ Parkinson'S Disease|October 25, 2024
CSF d18:1 sphingolipid species in Parkinson disease and dementia with Lewy bodies with and without GBA1 variantsStefanie Lerche, Isabel Wurster, Enza Maria Valente, et al.
Journal of Alzheimer'S Disease : JAD|March 23, 2011
Tau transgenic mice as models for cerebrospinal fluid tau biomarkersDonna M Barten, Gregory W Cadelina, Nina Hoque, et al.
Pageof 4